An essay describing one man's struggle with whether or not to take the pre-exposure prophylaxis (PrEP) drug Truvada cited a study that tracked PrEP retention rates among men who have sex with men in three U.S. cities. The study, "Evaluation of a program using Emtricitabine/Tenofovir (Truvada) as pre-exposure prophylaxis (PrEP) for HIV," was conducted in collaboration with The Miriam Hospital (Dr. Philip A. Chan, principal investigator), and collected data from PrEP clinical care programs in three mid-sized U.S. cities. Dr. Amy Nunn was a co-investigator and subcontract PI for the project.
CHER/Miriam research cited in New York Times essay
September 22, 2017